Log in

Relevant bibliographies by topics / III colorectal cancer

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'III colorectal cancer'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'III colorectal cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "III colorectal cancer"

1

Wang, Ning, Yang Chen, Yuchen Han, et al. "Proteomic analysis shows down-regulations of cytoplasmic carbonic anhydrases, CAI and CAII, are early events of colorectal carcinogenesis but are not correlated with lymph node metastasis." Tumori Journal 98, no. 6 (2012): 783–91. http://dx.doi.org/10.1177/030089161209800617.

Full text

Abstract:

Aim The aim of the study was to screen the markedly down-regulated proteins in colorectal cancer and analyze their relationship to carcinogenesis, cancer progression and pathological aspects. Methods Proteomic analysis was preformed on six fresh colorectal cancer tissues and paired normal colorectal mucosa by two-dimensional differential gel electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Two markedly down-regulated proteins among the proteins, of which the expressions were significantly decreased in colorectal cancer compared to normal mucosa,

APA, Harvard, Vancouver, ISO, and other styles

2

Compton, Carolyn C., L. Peter Fielding, Lawrence J. Burgart, et al. "Prognostic Factors in Colorectal Cancer." Archives of Pathology & Laboratory Medicine 124, no. 7 (2000): 979–94. http://dx.doi.org/10.5858/2000-124-0979-pficc.

Full text

Abstract:

Abstract Background.—Under the auspices of the College of American Pathologists, the current state of knowledge regarding pathologic prognostic factors (factors linked to outcome) and predictive factors (factors predicting response to therapy) in colorectal carcinoma was evaluated. A multidisciplinary group of clinical (including the disciplines of medical oncology, surgical oncology, and radiation oncology), pathologic, and statistical experts in colorectal cancer reviewed all relevant medical literature and stratified the reported prognostic factors into categories that reflected the strengt

APA, Harvard, Vancouver, ISO, and other styles

3

Li, Chenglong, Qian Pei, Hong Zhu, et al. "Survival nomograms for stage III colorectal cancer." Medicine 97, no. 49 (2018): e13239. http://dx.doi.org/10.1097/md.0000000000013239.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Malatay González, Carlos Humberto, Juan Bernardo Pazmiño Palacios, Luis Andrés Idrovo Murillo, Jhónatan Miguel Siguencia Muñoz, and Adriana Ximena Bravo Andrade. "Experiencia Quirúrgica en el Manejo del Cáncer de Recto. Hospital de SOLCA, Guayaquil – Ecuador." Revista Médica del Hospital José Carrasco Arteaga 12, no. 2 (2020): 92–97. http://dx.doi.org/10.14410/2020.12.2.ao.13.

Full text

Abstract:

BACKGROUND: Colorectal cancer is the third most common among malignant neoplasms worldwide. Treatment choice depends on the location of the tumor, among other factors, and varies from local excision to abdominoperineal resection, adjuvant or neoadjuvant therapy can be needed, depending on clinical stage. The purpose of this study was to determine the most common histological type of rectal cancer, establish the most frequent clinical stage at diagnosis, the most common surgical technique and complications. METHODOLOGY: A cross-sectional study was carried out, with 160 patients treated in the d

APA, Harvard, Vancouver, ISO, and other styles

5

Wang, Yuwei, Yadong Long, Ye Xu, et al. "Prognostic and Predictive Value of CpG Island Methylator Phenotype in Patients with Locally Advanced Nonmetastatic Sporadic Colorectal Cancer." Gastroenterology Research and Practice 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/436985.

Full text

Abstract:

Purpose. In the present study, the prognostic significance of CpG island methylator phenotype (CIMP) in stage II/III sporadic colorectal cancer was evaluated using a five-gene panel.Methods. Fifty stage II/III colorectal cancer patients who received radical resection were included in this study. Promoter methylation of p14ARF, hMLH1, p16INK4a, MGMT, and MINT1 was determined by methylation specific polymerase chain reaction (MSP). CIMP positive was defined as hypermethylation of three or more of the five genes. Impact factors on disease-free survival (DFS) and overall survival (OS) were analyze

APA, Harvard, Vancouver, ISO, and other styles

6

Takashima, Atsuo, Kenichi Miyamoto, Yuya Sato, et al. "Efficacy of aspirin for stage III colorectal cancer: A randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial)." Journal of Clinical Oncology 37, no. 15_suppl (2019): TPS3623. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps3623.

Full text

Abstract:

TPS3623 Background: Adjuvant chemotherapy is the current standard treatment for stage III colorectal cancer after curative resection. However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy. Recently, several observational studies suggested the anti-tumor effect of aspirin for advanced colorectal cancer. The main mechanism of the anti-tumor effect by aspirin may be to suppress cyclooxygenase activity in the arachidonic acid cascade and to inhibit the production of prostaglandins involved in tumor growth. So far, aspirin showed

APA, Harvard, Vancouver, ISO, and other styles

7

Li, Tao, Guoliang Liu, Jiannan Li, et al. "Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review." Journal of International Medical Research 49, no. 4 (2021): 030006052110070. http://dx.doi.org/10.1177/03000605211007050.

Full text

Abstract:

Radical resection with or without adjuvant chemotherapy is a common option for stage II and III colorectal cancer. Few reports exist regarding gastric tumorigenesis, including gastric cancer, gastric intraepithelial neoplasia, and gastric stromal tumor, in patients who received this protocol as the standard treatment for colorectal cancer. We present two cases of gastric tumorigenesis in patients with colorectal cancer following radical resection combined with adjuvant chemotherapy. Both patients underwent gastrectomy and D2 lymphadenectomy for their gastric tumors; neither patient developed r

APA, Harvard, Vancouver, ISO, and other styles

8

Anuraga, Gangga, Wan-Chun Tang, Nam Phan, et al. "Comprehensive Analysis of Prognostic and Genetic Signatures for General Transcription Factor III (GTF3) in Clinical Colorectal Cancer Patients Using Bioinformatics Approaches." Current Issues in Molecular Biology 43, no. 1 (2021): 2–20. http://dx.doi.org/10.3390/cimb43010002.

Full text

Abstract:

Colorectal cancer (CRC) has the fourth-highest incidence of all cancer types, and its incidence has steadily increased in the last decade. The general transcription factor III (GTF3) family, comprising GTF3A, GTF3B, GTF3C1, and GTFC2, were stated to be linked with the expansion of different types of cancers; however, their messenger (m)RNA expressions and prognostic values in colorectal cancer need to be further investigated. To study the transcriptomic expression levels of GTF3 gene members in colorectal cancer in both cancerous tissues and cell lines, we first performed high-throughput scree

APA, Harvard, Vancouver, ISO, and other styles

9

Schindler, Isabell, Patricia Grabowski, Iannis Anagnostopoulos, et al. "Neuroendocrine differentiation in stage III–IV colorectal cancer." Gastroenterology 118, no. 4 (2000): A511. http://dx.doi.org/10.1016/s0016-5085(00)84170-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tuma, Rabiya S. "Brivanib Fails in Phase III Colorectal Cancer Trial." Oncology Times 34, no. 4 (2012): 28–29. http://dx.doi.org/10.1097/01.cot.0000413013.92927.c5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "III colorectal cancer"

1

Begum, Mubeena. "Gene expression profiles and clinical parameters for survival prediction in stage II and III colorectal cancer." [Tampa, Fla] : University of South Florida, 2006. http://purl.fcla.edu/usf/dc/et/SFE0001554.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Obayashi(Nishiuchi), Aya. "MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer." Kyoto University, 2020. http://hdl.handle.net/2433/253179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Dandash, Fatima. "In vitro anticancer activity of new gold (III) porphyrin complexes in colon cancer cells." Thesis, Limoges, 2017. http://www.theses.fr/2017LIMO0086.

Full text

Abstract:

Le cancer colorectal (CCR) est le troisième cancer le plus commun diagnostiqué dans le monde entier. Les limites de la chimiothérapie à base de cisplatine ont incité les scientifiques à rechercher de nouveaux médicaments anti-cancéreux à base de métal. Les complexes à base d’or(III) ont été parmi les plus largement étudiés puisqu’ils ont montré une plus importante cytotoxicité in vitro que le cisplatine ainsi que des activités anti-cancéreuse in vivo dans le CCR, mais leur utilisation clinique a été limitée en raison de leur faible stabilité dans des conditions physiologiques. De nouveaux comp

APA, Harvard, Vancouver, ISO, and other styles

4

Calvete, Joanne Amanda. "Pre-clinical studies with the novel colorectal cancer targeted immunotoxin, ICI D0490." Thesis, University of Newcastle Upon Tyne, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.336268.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lord, Rianne M., Markus Zegke, I. R. Henderson, C. M. Pask, H. J. Shepherd та P. C. McGowan. "β‐Ketoiminato Iridium(III) Organometallic Complexes: Selective Cytotoxicity towards Colorectal Cancer Cells HCT116 p53‐/‐". 2018. http://hdl.handle.net/10454/16755.

Full text

Abstract:

Yes<br>This report presents a new library of organometallic iridium(III) compounds of the type [Cp*IrCl(L)] (Cp*=pentamethylcyclopentadienyl and L=a functionalized β‐ketoiminato ligand) showing moderate to high cytotoxicity against a range of cancer cell lines. All compounds show increased activity towards colorectal cancer, with preferential activity observed against the immortalized p53‐null colorectal cell line, HCT116 p53‐/‐, with sensitivity factors (SF) up to 26.7. Additionally, the compounds have excellent selectivity for cancerous cells when tested against normal cell types, with selec

APA, Harvard, Vancouver, ISO, and other styles

6

Chen, Chia-Hua, та 陳家嬅. "β-1,4-Galactosyltransferase III suppresses β1 integrin mediated invasive phenotypes and negatively correlates with metastasis in colorectal cancer". Thesis, 2014. http://ndltd.ncl.edu.tw/handle/f3679h.

Full text

Abstract:

博士<br>國立臺灣大學<br>解剖學暨細胞生物學研究所<br>102<br>Metastasis often occurs in colorectal cancer (CRC) patients and is the main difficulty in cancer treatment. The upregulation of poly-N-acetyllactosamine related glycosylation is found in CRC patients and is associated with progression and metastasis in cancer. B4GALT3 is an enzyme responsible for poly-N-acetyllactosamine synthesis, and therefore we investigated its expression in CRC patients. We found that B4GALT3 negatively correlated with poorly differentiated histology (P < 0.001), advanced stages (P = 0.0052), regional lymph node metastasis (P = 0.001

APA, Harvard, Vancouver, ISO, and other styles

7

Gauß, Korbinian Andreas. "ERCC1-Expression unter 5-FU- und Oxaliplatin-basierter multimodaler Therapie beim Rektumkarzinom (cUICC-Stadien II und III) - Potentielle prädiktive und prognostische Bedeutung." Doctoral thesis, 2014. http://hdl.handle.net/11858/00-1735-0000-0022-5EBB-B.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "III colorectal cancer"

1

Newell-Price, John, Alia Munir, and Miguel Debono. Obesity: differential diagnosis. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0081.

Full text

Abstract:

This topic addresses the causes and consequences of obesity, defined as a body mass index (BMI) of 30 or above. While BMI is the most commonly used measure of obesity, the waist-to-height ratio correlates better with visceral obesity. At least 1.1 billion adults are overweight worldwide, but a medical cause for obesity is found in less than 1 out of every 100 cases. The health consequences of obesity are diverse and serious. Approximately 50% of all hypertension is secondary to obesity, and the heart may also be harmed by obesity-induced chronic volume overload and ischaemic heart disease. Obe

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "III colorectal cancer"

1

Sorbye, Halfdan. "Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer." In Early Gastrointestinal Cancers II: Rectal Cancer. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08060-4_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Evrard, Serge. "Limits of Colorectal Liver Metastases Resectability: How and Why to Overcome Them?" In Early Gastrointestinal Cancers II: Rectal Cancer. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08060-4_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Seymour, Matthew, and Sarah Brown. "Targeted Therapy for Advanced Colorectal Cancer." In A Practical Guide to Designing Phase II Trials in Oncology. John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118763612.ch12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Metzger, U., W. Weder, M. Röthlin, and F. Largiadèr. "Phase II Study of Intra-arterial Fluorouracil and Mitomycin-C for Liver Metastases of Colorectal Cancer." In Supportive Care in Cancer Patients II. Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-84138-5_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Boussioutas, Alex, Stephen Fox, Iris Nagtegaal, et al. "Colorectal cancer." In Oxford Textbook of Oncology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199656103.003.0039.

Full text

Abstract:

This chapter covers colorectal cancer, and includes information on epidemiology, risk factors (chronic inflammation/inflammatory bowel disease, radiation, diet and lifestyle, post cholecystectomy, diabetes, obesity and insulin resistance, cigarette smoking, alcohol, ureterocolic anastamosis, and genetic risk factors, screening, and chemoprevention (aspirin, and NSAIDS), the molecular biology and pathology of colorectal cancer, colorectal carcinoma (location, pathologic prognostic markers, and predictive markers), surgical management (colonic cancer and inflammatory bowel disease, hereditary non-polyposis colonic cancer or HNPCC, presenting as an emergency, treatment of polyp or early cancers, liver and lung metastasis, peritoneal disease, results of surgery and treatment for colon cancer, medical management of early stage disease, adjuvant chemotherapy for stage III disease (T1-4, N1-2M0), adjuvant therapy of patients with resected stage II colon cancer, radiotherapy, multidisciplinary care and special groups, the role of allied teams, and surveillance and follow-up.

APA, Harvard, Vancouver, ISO, and other styles

6

Boussioutas, Alex, Stephen Fox, Iris Nagtegaal, et al. "Colorectal cancer." In Oxford Textbook of Oncology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199656103.003.0039_update_001.

Full text

Abstract:

This chapter covers colorectal cancer, and includes information on epidemiology, risk factors (chronic inflammation/inflammatory bowel disease, radiation, diet and lifestyle, post cholecystectomy, diabetes, obesity and insulin resistance, cigarette smoking, alcohol, ureterocolic anastamosis, and genetic risk factors, screening, and chemoprevention (aspirin, and NSAIDS), the molecular biology and pathology of colorectal cancer, colorectal carcinoma (location, pathologic prognostic markers, and predictive markers), surgical management (colonic cancer and inflammatory bowel disease, hereditary non-polyposis colonic cancer or HNPCC, presenting as an emergency, treatment of polyp or early cancers, liver and lung metastasis, peritoneal disease, results of surgery and treatment for colon cancer, medical management of early stage disease, adjuvant chemotherapy for stage III disease (T1-4, N1-2M0), adjuvant therapy of patients with resected stage II colon cancer, radiotherapy, multidisciplinary care and special groups, the role of allied teams, and surveillance and follow-up.

APA, Harvard, Vancouver, ISO, and other styles

7

Sen, Fatma, and Kezban Nur Pilanci. "Adjuvant Systemic Therapy in Stage II and III Colon Cancer." In Colorectal Cancer - From Pathogenesis to Treatment. InTech, 2016. http://dx.doi.org/10.5772/63208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wedding, U., R. Kath, K. Höffken, and A. de Gramont. "Oxaliplatin: Clinical Experience of Phase I and II Trials and Results of a Randomised Phase II-III Trial in First-Line Therapy with Advanced Colorectal Cancer." In Contributions to Oncology. S. Karger AG, 1999. http://dx.doi.org/10.1159/000425846.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "III colorectal cancer"

1

Egu, John Chinonso, Krisztián Moldován, Petra Herman, István Fábián, Ferenc Fenyvesi, and József Kalmár. "Cisplatin loaded hybrid aerogel microparticles for cervical and colorectal cancer chemotherapy." In III. Fiatal Technológusok Fóruma. MGYT Gyógyszertechnológiai Szakosztály, 2020. http://dx.doi.org/10.14232/ftf.2020.op9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Katoh, Hiroshi, Keishi Yamashita, Akira Ooki, David Sidransky, and Masahiko Watanabe. "Abstract 4947: Homeobox geneHOPXis epigenetically silenced cancer-specifically in colorectal cancer and predicts poor prognosis in stage III colorectal cancer." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4947.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lalosevic, MS, Z. Krivokapic, M. Micev, et al. "PERINEURAL INVASION PREDICTS POOR PROGNOSIS IN STAGE I-III COLORECTAL CANCER PATIENTS." In ESGE Days. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1704755.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kobayashi, Yusuke, Kensuke Kumamoto, Yoshiko Matsumoto, Motonobu Saito, Tatsuo Shimura, and Seiichi Takenoshita. "Abstract 3415: PAICS is the prognostic marker in colorectal cancer patients with stage III." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3415.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Inoue, Yoshikage, Nobuyuki Kakiuchi, Kenichi Yoshida, et al. "Abstract 4385: Landscape of driver gene mutations in stage II and stage III colorectal cancer." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Inthagard, Jitwadee, Donald McMillan, Joanne Edwards, and Antonia Roseweir. "Abstract A102: The prognostic impact of different immune landscapes in patients with stage I-III colorectal cancer." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 17-20, 2019; Boston, MA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm19-a102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ma, Dongling, Yaqi Xue, Andrew Fesler, et al. "Abstract 1968: Systematic validation of microRNA based prognostic biomarkers for stage II, III and IV colorectal cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1968.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stachtea, Xanthi, Andreas Lindner, Manuela Salvucci, et al. "Abstract 2676: Hyperplexed immunofluorescence analysis (Cell DIVETM) of immune-related tumor heterogeneity in stage III colorectal cancer." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-2676.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Santos, P., D. Murtinho, AS Pires Lourenço, et al. "PO-416 Cytotoxicity of Ru (II) and Ru (III) salen complexes against breast and colorectal cancer cell lines." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.442.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Smith, David H., Niels F. Jensen, Ib J. Christensen, et al. "Abstract 1912: An explorative analysis ofERCC1/ERCC4copy number alterations in a chemonaive stage III colorectal cancer patient cohort." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1912.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!